3月30日，智云健康（09955）发布2024年度业绩公告。面对严峻的市场环境，公司通过主动优化业务结构实现稳健经营，全年营收达34.9亿元人民币，毛利率稳中略升，达24.7%。而净亏损扩大主要源于非核心业务处置的一次性影响，并非经营性原因。
财报指出，短期发展策略上，公司将重点推进“AI SaaS+P2M”（从患者到工业）战略，通过自营药品销售确保现金流稳定；中期计划，将依托医疗数据资产构建商业化变现模型；长期目标则是整合医院、药店、药企、患者及支付方等医疗生态各方资源，打造个人慢病管理闭环。
此次业务调整体现了智云健康在战略聚焦与长期布局上的平衡，标志着智云健康从规模扩张向质量提升的战略转型迈出关键一步。随着战略重心的明确，公司未来的盈利能力和市场竞争力或将进一步提升，后续发展值得市场关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.